1-4 of 4
Kari B. Wisinski
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J

Roisin M. Connolly, Victoria Wang, David M. Hyman, Petros Grivas, Edith P. Mitchell, John J. Wright, Elad Sharon, Robert J. Gray, Lisa M. McShane, Larry V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Jue Wang, Kari B. Wisinski, James V. Tricoli, Barbara A. Conley, Lyndsay N. Harris, Carlos L. Arteaga, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1273–1280.
https://doi.org/10.1158/1078-0432.CCR-23-0633
Published: 01 April 2024
View article titled, Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal <em>HER2</em>-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J
Open the PDF for Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal <em>HER2</em>-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J in another window
Includes: Supplementary data
Journal Articles

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Atish D. Choudhury, Celestia S. Higano, Johann S. de Bono, Natalie Cook, Dana E. Rathkopf, Kari B. Wisinski, Juan Martin-Liberal, Mark Linch, Elisabeth I. Heath, Richard D. Baird, Javier García-Carbacho, Miguel Quintela-Fandino, Simon T. Barry, Elza C. de Bruin, Steve Colebrook, George Hawkins, Teresa Klinowska, Brijesh Maroj, Ganesh Moorthy, Peter G. Mortimer, Michele Moschetta, Myria Nikolaou, Liz Sainsbury, Geoffrey I. Shapiro, Lillian L. Siu, Aaron R. Hansen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2257–2269.
https://doi.org/10.1158/1078-0432.CCR-21-3087
Published: 01 June 2022
View article titled, A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer

Cynthia X. Ma, Vera Suman, Matthew P. Goetz, Donald Northfelt, Mark E. Burkard, Foluso Ademuyiwa, Michael Naughton, Julie Margenthaler, Rebecca Aft, Richard Gray, Amye Tevaarwerk, Lee Wilke, Tufia Haddad, Timothy Moynihan, Charles Loprinzi, Tina Hieken, Erica K. Barnell, Zachary L. Skidmore, Yan-Yang Feng, Kilannin Krysiak, Jeremy Hoog, Zhanfang Guo, Leslie Nehring, Kari B. Wisinski, Elaine Mardis, Ian S. Hagemann, Kiran Vij, Souzan Sanati, Hussam Al-Kateb, Obi L. Griffith, Malachi Griffith, Laurence Doyle, Charles Erlichman, Matthew J. Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (22): 6823–6832.
https://doi.org/10.1158/1078-0432.CCR-17-1260
Published: 14 November 2017
View article titled, A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <em>PIK3CA</em>-Mutant ER-Positive and HER2-Negative Breast Cancer
Open the PDF for A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <em>PIK3CA</em>-Mutant ER-Positive and HER2-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer

Kari B. Wisinski, Amye J. Tevaarwerk, Mark E. Burkard, Murtuza Rampurwala, Jens Eickhoff, Maria C. Bell, Jill M. Kolesar, Christopher Flynn, Glenn Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (11): 2659–2667.
https://doi.org/10.1158/1078-0432.CCR-15-2365
Published: 31 May 2016
View article titled, Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2<sup>+</sup> Breast Cancer
Open the PDF for Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2<sup>+</sup> Breast Cancer in another window